Kevin Michael Krause - 15 Mar 2024 Form 4 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Role
Chief Strategy Officer
Signature
/s/ Lucy Day, Attorney-in-Fact for Kevin Michael Krause
Issuer symbol
ANTX
Transactions as of
15 Mar 2024
Net transactions value
$0
Form type
4
Filing time
18 Mar 2024, 19:28:19 UTC
Previous filing
11 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANTX Common Stock Award $0 +30,000 +1567% $0.000000 31,914 15 Mar 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANTX Stock Option (right to buy) Award $0 +60,000 $0.000000 60,000 15 Mar 2024 Common Stock 60,000 $3.00 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These restricted stock units vest as follows: 1/16th of the shares vests quarterly over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date.
F2 The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date.